ARTICLE | Deals
AAV tech pays off for Ultragenyx as Daiichi digs into gene therapy
April 1, 2020 11:26 PM UTC
Updated on Apr 1, 2020 at 11:49 PM UTC
Ultragenyx's AAV manufacturing deal with Daiichi Sankyo highlights the former's return on its investment in Dimension Therapeutics, and the latter's growing interest in gene therapy.
The deal, announced Wednesday, gives Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) $125 million in cash and $75 million via an equity investment. Daiichi Sankyo Co. Ltd. (Tokyo:4568) gains non-exclusive rights to Ultragenyx’s HeLa producer cell line (PCL) platform and HEK293 transient transfection system for AAV manufacturing...